BD Diagnostic Systems, Sparks, MD, announces that the BD Phoenix™ Automated Microbiology System has received FDA 510(k) clearance for sale in the U.S.A. BD Phoenix is a fully automated rapid system for the identification and susceptibility testing of clinically relevant bacteria. Designed for both small volume and large volume laboratories, the Phoenix System incorporates an easy-to-use workflow, sophisticated instrumentation and advanced software to provide rapid and reliable results. The Phoenix System's panels are intended for identification only, susceptibility only or in combination. Susceptibility testing utilizes doubling concentrations to determine classic MIC results. Identification testing incorporates forty-five self-indicating fluorogenic and chromogenic substrates for reagent-free reactions. The FDA clearance includes the Phoenix instrument, software and a limited menu of antimicrobial agents for in vitro testing. For further information contact your BD Diagnostic Systems representative.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.